Value20202021202220232024TTMSelling/general/admin expenses46.02 M53.08 M60.32 M51.79 M52.49 M52.91 MResearch & development17.42 M28.5 M49.64 M64.66 M132.93 M205.25 MOperating income37.29 M55.28 M99.64 M75.07 M145.85 M218.33 MNon-Operating Income, Total8.1 M3.14 M2.62 M4.36 M15.07 M12.76 MInterest expense, net of interest capitalized7.26 M5.5 M3.19 M1.25 M14 K—Non-Operating Income, excl. Interest Expenses789 K-2.65 M-2.7 M-3.84 M-28 K-14 KUnusual income/expense58 K292 K2.13 M6.95 M15.09 M12.77 MPretax income45.39 M58.42 M102.25 M70.71 M130.78 M302.52 MEquity in earnings——————Taxes00083 K90 K—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations45.39 M58.42 M102.25 M70.8 M130.87 M205.75 MDiscontinued operations——————Net income45.39 M58.42 M102.25 M70.8 M130.87 M205.75 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders45.39 M58.42 M102.25 M70.8 M130.87 M205.75 MBasic earnings per share (Basic EPS)——-2.74-1.82-2.32-3Diluted earnings per share (Diluted EPS)——-2.74-1.82-2.32-3Average basic shares outstanding——37.32 M38.9 M56.3 M266.16 MDiluted shares outstanding——37.32 M38.9 M56.3 M266.16 MEBITDA—-53.59 M-98.96 M-75.07 M-144.35 M—EBIT—-56.55 M-101.59 M-75.57 M-145.85 M—Cost of revenue—1.28 M1.95 M500 K0—Other cost of goods sold—1.28 M1.95 M500 K0—Depreciation & amortization (cash flow)2.74 M2.96 M2.63 M500 K1.5 M2.04 M
EyePoint Inc
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner.
In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.